OTCMKTS:FSNUY

Fresenius SE & Co. Q1 2025 Earnings Results & Report

Fresenius SE & Co. logo
$14.78 -0.01 (-0.07%)
As of 03:59 PM Eastern

Fresenius SE & Co. beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 7, 2025. The company reported EPS of $0.23 versus the $0.2170 consensus estimate, while revenue of $5.92 billion topped the $5.41 billion estimate by $513.12 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Fresenius SE & Co. EPS Results

Actual EPS
$0.23
Consensus EPS
$0.2170
Beat/Miss
Beat by +$0.0130
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

Fresenius SE & Co. Revenue Results

Actual Revenue
$5.92 billion
Expected Revenue
$5.41 billion
Beat/Miss
Beat by +$513.12 million
YoY Revenue Growth
N/A

Conference Call Resources

Fresenius SE & Co. Q1 2025 Earnings FAQ

Fresenius SE & Co. (OTCMKTS:FSNUY) reported earnings of $0.23 per share for Q1 2025, beating the consensus estimate of $0.2170. The report was announced on Wednesday, May 7, 2025.

Fresenius SE & Co. reported revenue of $5.92 billion for Q1 2025, against a consensus estimate of $5.41 billion.

Fresenius SE & Co. Earnings Headlines

Fresenius plans to sell around 13.4 million FMC shares
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.tc pixel
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain.

Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.

Michael Sen has served as Fresenius’s chief executive officer since 2022. Through its businesses, the company provides products and services across areas including hospital care, pharmaceuticals and medical technology.

View Fresenius SE & Co. Profile